Genmab (GMAB) completes DKK 615m share buy-back, holds 4.45% treasury

Rhea-AI Filing Summary

Genmab A/S has completed its share buy-back program, repurchasing 342,130 shares for a total of 615,105,001 DKK to meet commitments under its Restricted Stock Unit program. The program, launched on February 17, 2026, finished on March 13, 2026, earlier than expected.

From March 9 to March 13, 2026, Genmab bought 93,130 shares, including 25,130 shares on March 13 at an average price of 1,717.39 DKK. After these transactions, Genmab holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MARCH 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated March 16, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: March 16, 2026

Exhibit 99.1

Completion of Share Buy-back Program

Company Announcement

COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026.

On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of 725 million DKK to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than March 31, 2026.

The following transactions were executed under the program from March 9, 2026 to March 13, 2026:

			No. of shares			Average price (DKK)			Total value (DKK)
Accumulated through last announcement			249,000						452,588,620
March 9, 2026			18,000			1,723.04			31,014,720
March 10, 2026			15,000			1,781.03			26,715,450
March 11, 2026			15,000			1,767.72			26,515,800
March 12, 2026			20,000			1,755.62			35,112,400
March 13, 2026			25,130			1,717.39			43,158,011
Total			93,130						162,516,381
Accumulated under the program			342,130						615,105,001

Following these transactions, Genmab holds 2,859,663 shares as treasury shares, corresponding to 4.45% of the total share capital and voting rights.

The share buy-back program has been undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 05 dated February 17, 2026.

About Genmab

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:

Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no.16 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Completion of Share Buy-back Program

The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no.16 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

FAQ

What did Genmab (GMAB) announce in its March 2026 Form 6-K?

Genmab announced the completion of its share buy-back program on March 13, 2026. The company repurchased 342,130 shares for 615,105,001 DKK to support its Restricted Stock Unit program commitments.

How many shares did Genmab (GMAB) repurchase and at what total value?

Genmab repurchased 342,130 shares under its buy-back program for a total consideration of 615,105,001 DKK. This included 93,130 shares bought between March 9 and March 13, 2026 at various average prices in DKK.

Why did Genmab (GMAB) conduct this share buy-back program?

Genmab conducted the share buy-back program to honor commitments under its Restricted Stock Unit program. Repurchased shares are held as treasury shares and can be used to settle equity-based compensation obligations to employees and management.

What percentage of Genmab’s (GMAB) share capital is now held as treasury shares?

Following completion of the buy-back, Genmab holds 2,859,663 shares as treasury shares. This represents 4.45% of the company’s total share capital and voting rights after the March 2026 transactions.

Over what period did Genmab (GMAB) execute the final buy-back transactions?

The final phase of the buy-back program ran from March 9 to March 13, 2026. During this period, Genmab repurchased 93,130 shares at average prices between 1,717.39 DKK and 1,781.03 DKK per share.

Under which regulations was Genmab’s (GMAB) buy-back program carried out?

The buy-back program was executed in accordance with Regulation (EU) No. 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052. These rules, often called the Safe Harbour Regulation, set conditions for issuer share repurchases.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 27.8 KB